![]() |
|
|

2
Department of Internal Medicine, School of Medicine of Zaragoza, Spain,
*
INSERM U400, School of Medicine of Créteil, France and
Department of Pharmacology and Physiology, Facultad de Medicina, 50009 Zaragoza, Spain.
2To whom correspondence should be addressed. E-mail: joalda{at}posta.unizar.es.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: hypertension isoflavonoids genistein soy milk equol humans
| INTRODUCTION |
|---|
|
|
|---|
| SUBJECTS AND METHODS |
|---|
|
|
|---|
Overall, 40 people with essential hypertension (25 men aged 1870 y and 15 women aged 5070 y) were included in the study (no cause of high blood pressure was detected after complete investigation). Patients had hypertension of degree 1 or 2 according to the guidelines of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (8
), i.e., in repeated blood pressure measurements (3 d in 3 consecutive weeks), they had systolic blood pressure (SBP)3
between 140 and 179 mm Hg and diastolic blood pressure (DBP) between 90 and 109 mm Hg. Half of the 40 subjects included were untreated hypertensives (12 took thiazide diuretics, 6 took enalapril and 2 took amlodipine).
Measurement of blood pressure.
Blood pressure was measured by sphygnomanometry, according to the recommendations of the American Heart Association (9
). In particular, subjects rested for 1 h before blood pressure monitoring began. All measurements were made between 0900 and 1100 h by one observer who was unaware of treatment group. Four recordings were performed in duplicate (in each arm and in recumbent or seated position). When duplicate values showed a difference >5 mm Hg, the measurements were repeated.
Diet protocol.
To select a soy preparation for the study, isoflavonoid contents were measured in commercially available preparations, including three different soy milks, soy lecithin and soy germ. Of these, daidzein and genistein contents in the selected soy milk (Calcimel, Santivery s.a., Barcelona, Spain; see Table 1
) were 2 times higher than in soy lecithin and 10 times higher than in soy germ. Therefore, this soy milk was selected for the study.
|
Subjects were asked not to change dietary habits (Mediterranean diet) during the study, particularly the consumption of salt, fruit, vegetables and fat [for influence of dietary habits on blood pressure see (10
)].
Ethical aspects.
Subjects were informed about objectives, methods, potential benefits and/or disadvantages of the trial and a written informed consent was obtained before inclusion in the study. Subjects were free to decide about their inclusion in the study or to stop at any time.
Study protocol.
A 4-wk washout period, without medication (antihypertensive or other), was scheduled. Then, subjects were given 500 mL soy or cows milk twice daily for 3 mo. The allocation of the diet, soy or cows milk, was made at random. A twice-a-day administration was used on the basis of previous pharmacokinetic data for isoflavonoids (11
) showing a plasma half-life of
6 h.
The trial as well as the statistical analysis of the results was carried out without awareness of treatment group assignment. The primary criterion of efficacy was a reduction in blood pressure due to treatment. Isoflavonoid concentrations were measured in milk and urine by HPLC (12
).
Statistical analysis.
Statistical analysis was performed using a StatView program (version 4.02, Abacus Concept, Inc., Berkeley, CA). The following tests were conducted:
2 test for comparison of qualitative variables; nonpaired bilateral Students t tests for comparison of quantitative variables (variances were firstly compared by Fishers F-test to show a lack of significant differences); and correlation/covariance analysis by using Fishers r-to-Z transform. A difference was considered significant when the level of significance of the bilateral test was
0.05.
Distribution of qualitative variables was expressed as the frequency of the different observed values. Distribution of quantitative variables was expressed as mean ± SD.
| RESULTS |
|---|
|
|
|---|
Effects on blood pressure of soy milk vs. cows milk.
Soy milk decreased blood pressure significantly and more than cows milk (P < 0.001, Fig. 1
). SBP, DBP and MBP decreased by 18.4 ± 10.7, 15.9 ± 9.8 and 16.7 ± 9.0 mm Hg, in the soy milk group, respectively, and by 1.4 ± 7.2, 3.7 ± 5.0 and 3.0 ± 4.6 in the cows milk group.
|
Correlation/covariance analysis of the decrease in blood pressure as a function of daily urinary isoflavonoid excretion showed that urinary genistein, but not daidzein was strongly correlated, particularly for the diastolic values. The decreases in diastolic blood pressure were negatively correlated (r = -0.588, P = 0.002) with urinary genistein excretion at the end of the study (Fig. 2
). Urinary equol excretion tended to be negatively correlated (r = -0.279, P = 0.189) with the decrease in systolic blood pressure.
|
| DISCUSSION |
|---|
|
|
|---|
Our study confirms and extends to human hypertension previous observations by Nevala et al. (5
) showing that a soy-based diet attenuates the development of hypertension in spontaneously hypertensive rats [see also (13
)] and those of Washburn et al. (6
) that soy protein supplementation (isocaloric supplements containing 34 mg of phytoestrogens) significantly reduced diastolic blood pressure in perimenopausal women. As expected, the soy-based diet lowered diastolic blood pressure more in subjects with mild-to-moderate essential hypertension (-16 mm Hg) than in healthy perimenopausal women (-5 mm Hg).
In contrast with the above observations, Hodgson et al. (7
) reported that one tablet containing 55 mg isoflavonoids (30 mg genistein, 16 mg biochanin A, 1 mg of daidzein and 8 mg of formononetin), taken daily for 8 wk had no significant hypotensive action in essential hypertensive patients. Differences from our present results may have had several explanations, including the greater amount of isoflavonoids given here with the natural soy milk (80 mg genistein + 63 mg daidzein/d), the short half-life of genistein in humans (11
,14
), allowing a better 24-h blood pressure control with twice-a-day treatment in the present study and in the study of Washburn et al. (6
) (vs. once-a-day tablets in Hodgsons study) and finally, soy proteins were lacking in the tablets and can contribute to the hypotensive action of soy-based diets.
The correlation between the blood pressurelowering effect of soy milk and urinary genistein excretion (and to a lesser extent with urinary equol excretion) suggests that isoflavonoids can mediate, at least in part, the hypotensive actions of a soy diet. Indeed, some of us previously found that genistein possesses a similar salidiuretic profile and compares well with furosemide in the isolated, perfused rat kidney and is also natriuretic by the subcutaneous route in rats (2
). Moreover, equol also compared well with furosemide as a natriuretic agent in the isolated, perfused rat kidney (3
). However, natriuresis by oral equol in rats was only 18% of that obtained with furosemide (3
), probably due to protein binding and extensive glucuro-conjugation. The same should be true for genistein, which is also extensively sulfo- and glucuro-conjugated in humans (14
). On the other hand, no attempt was made here to investigate potential natriuretic actions of the soy milk diet. In addition to natriuresis, genistein and equol possess vasorelaxant properties in animal models (1
,3
,4
), which can also play a role in the antihypertensive action of soy diets. Finally, Duarte et al. (15
) recently reported that the flavonoid quercetin (a chemical analog of genistein) possesses antihypertensive effects in spontaneously hypertensive rats due to its antioxidant properties.
In addition to isoflavonoids, protein or other components of soy milk may also contribute to its blood pressurelowering action. Soy diets have modestly, but significantly higher contents of arginine (a precursor of nitric oxide) than casein diets (16
). Therefore, the extent to which the modest natriuretic and vasorelaxant actions of genistein and equol contribute to the beneficial action of the soy diet in hypertension remains as an open question.
The blood pressurelowering action of a 3-mo soy milk diet was significant, but modest (-16 mm Hg in DBP vs. -4 mm Hg in the cows milk group). This investigation was performed in mild-to-moderate hypertensives and, to our knowledge, nothing is known concerning the magnitude of potential hypotensive actions in more severely hypertensive patients. Moreover, mild-to-moderate hypertension is the most frequent form of hypertension, and subjects can readily benefit from a modest diet-dependent reduction in blood pressure.
The above considerations raise an important public health concern. Indeed, after a very large number of reports showing beneficial aspects of a soy-based diet in cancer, osteoporosis and atherosclerosis [for a recent review see (17
)], others have recently expressed concern about reduction of mineral and vitamin intestinal absorption (due to soys phytic acid) and disorders in thyroid function [see, for example (18
)]. It is perhaps too early to place the antihypertensive actions of a soy-based diet in this debate. Indeed, our study had some possible flaws, i.e., the difference in taste between soy milk and cows milk can be recognized by the patients, and soy milk and cows milk were substantially different in fat and carbohydrate composition (Table 1)
, warranting a crossover design. Therefore, our study can be considered as preliminary, requiring subsequent trials for validation.
A final aspect of our results is whether genistein and/or daidzein can explain the blood pressurelowering action of a vegetarian diet [for a recent review see (19
)]. In this respect, it is important to stress that the amount of isoflavonoids in a vegetarian diet is highly variable, strongly depending on soy product consumption. On the other hand, a comparison of our results with those of Hodgson et al. (7
) suggests that only a soy-rich diet, containing large amounts of isoflavonoids, is required to obtain a blood pressurelowering action. Therefore, isoflavonoids should be only modest contributors to the blood pressurelowering action of a vegetarian diet (19
).
In conclusion, chronic soy milk consumption had modest, but significant hypotensive action in essential hypertensive patients. This hypotensive action was correlated with the urinay excretion of the isoflavonoid genistein. Further investigation is required to determine the relative contribution of isoflavonoids and soy proteins in the hypotensive actions of soy-based diets.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: DBP, diastolic blood pressure; MBP, mean blood pressure; SBP, systolic blood pressure. ![]()
Manuscript received 26 November 2001. Initial review completed 20 December 2001. Revision accepted 23 February 2002.
| LITERATURE CITED |
|---|
|
|
|---|
1. Nevala, R., Korpela, R. & Vapaatalo, H. (1998) Plant derived estrogens relax rat mesenteric artery in vitro. Life Sci 63:95-100.
2. Gimenez, I., Martinez, R. M., Lou, M., Mayoral, J. A., Garay, R. P. & Alda, J. O. (1998) Salidiuretic action by genistein in the isolated perfused rat kidney. Hypertension 31:706-711.
3. Gimenez, I., Lou, M., Vargas, F., Alvarez-Guerra, M., Mayoral, J. A., Martinez, R. M., Garay, R. P. & Alda, J. O. (1997) Renal and vascular action of equol in the rat. J. Hypertens. 15:1303-1308.[Medline]
4. Mishra, S. K., Abbot, S. E., Choudhury, Z., Cheng, M., Khatab, N., Maycock, N. J., Zavery, A. & Aaronson, P. I. (2000) Endothelium-dependent relaxation of rat aorta and main pulmonary artery by the phytoestrogens genistein and daidzein. Cardiovasc. Res. 46:539-546.
5. Nevala, R., Vaskonen, T., Vehniainen, J., Korpela, R. & Vapaatalo, H. (2000) Soy based diet attenuates the development of hypertension when compared to casein based diet in spontaneously hypertensive rat. Life Sci 66:115-124.[Medline]
6. Washburn, S., Burke, G. L., Morgan, T. & Anthony, M. (1999) Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 6:7-13.[Medline]
7. Hodgson, J. M., Puddey, I. B., Beilin, L. J., Mori, T. A., Burke, V., Croft, K. D. & Rogers, P. B. (1999) Effects of isoflavonoids on blood pressure in subjects with high-normal ambulatory blood pressure levels: a randomized controlled trial. Am. J. Hypertens. 12:47-53.[Medline]
8. Frohlich, E. D. (1993) The fifth Joint National Committee report on the detection, evaluation and treatment of high blood pressure. J. Am. Coll. Cardiol. 22:621-622.[Medline]
9. Fredich, E. D., Grim, C. & Labarthe, D. R. (1988) Recommendations for human blood pressure determination by sphygmomanometers. Circulation 77:501A-514A.
10. Volmer, W. M., Sacks, F. M. & Svetkey, L. P. (2001) New insights into the effects on blood pressure of diets low in salt and high in fruits and vegetables and low-fat diary products. Curr. Control Trials Cardiovasc. Med. 2:71-74.
11. Watanabe, S., Yamaguchi, M., Sobue, T., Takahashi, T., Miura, T., Arai, Y., Mazur, W., Wähälä, K. & Adlercreutz, H. L. (1998) Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J. Nutr. 128:1710-1715.
12. King, R. A., Broadbent, J. L. & Head, R. J. (1996) Absorption and excretion of the soy isoflavone genistein in rats. J. Nutr. 126:176-182.
13. Martin, D. S., Breitkopf, N. P., Eyster, K. M. & Williams, J. L. (2001) Dietary soy exerts an antihypertensive effect in spontaneously hypertensive female rats. Am. J. Physiol. 28:R553-R560.
14. Shelnutt, S. R., Cimino, C. O., Wiggins, P. A. & Badger, T. M. (2000) Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein. Cancer Epidemiol. Biomark. Prev. 9:413-419.
15. Duarte, J., Perez-Palencia, R., Vargas, F., Ocete, M. A., Perez-Vizcaino, F., Zarzuelo, A. & Tamargo, J. (2001) Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br. J. Pharmacol. 133:117-124.[Medline]
16. Dudasova, S. & Grancicova, E. (1992) Influence of casein and soy flour proteins on amino acid content in the liver of experimental animals. Physiol. Res. 41:411-416.[Medline]
17. Goldwyn, S., Lazinsky, A. & Wei, H. (2000) Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metab. Drug Interact 17:261-289.[Medline]
18. Fallon, S. & Enig, M.G. (2000) Soja: Consequences dune information manipulée. Nexus :9-20.
19. Beilin, L.J. & Burke, V. (1995) Vegetarian diet components, protein and blood pressure: which nutrients are important?. Clin. Exp. Pharmacol. Physiol. 22:195-198.[Medline]
This article has been cited by other articles:
![]() |
T. M. Cho, N. Peng, J. T. Clark, L. Novak, S. Roysommuti, J. Prasain, and J. M. Wyss Genistein Attenuates the Hypertensive Effects of Dietary NaCl in Hypertensive Male Rats Endocrinology, November 1, 2007; 148(11): 5396 - 5402. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Clerici, K. D. R. Setchell, P. M. Battezzati, M. Pirro, V. Giuliano, S. Asciutti, D. Castellani, E. Nardi, G. Sabatino, S. Orlandi, et al. Pasta Naturally Enriched with Isoflavone Aglycons from Soy Germ Reduces Serum Lipids and Improves Markers of Cardiovascular Risk J. Nutr., October 1, 2007; 137(10): 2270 - 2278. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mann, D. J. Rowlands, F. Y.L. Li, P. de Winter, and R. C.M. Siow Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression Cardiovasc Res, July 15, 2007; 75(2): 261 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. K. Welty, K. S. Lee, N. S. Lew, and J.-R. Zhou Effect of Soy Nuts on Blood Pressure and Lipid Levels in Hypertensive, Prehypertensive, and Normotensive Postmenopausal Women Arch Intern Med, May 28, 2007; 167(10): 1060 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R Matthan, S. M Jalbert, L. M Ausman, J. T Kuvin, R. H Karas, and A. H Lichtenstein Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects Am. J. Clinical Nutrition, April 1, 2007; 85(4): 960 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Erdman Jr., D. Balentine, L. Arab, G. Beecher, J. T. Dwyer, J. Folts, J. Harnly, P. Hollman, C. L. Keen, G. Mazza, et al. Flavonoids and Heart Health: Proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC J. Nutr., March 1, 2007; 137(3): 718S - 737S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Joy, R. C. M. Siow, D. J. Rowlands, M. Becker, A. W. Wyatt, P. I. Aaronson, C. W. Coen, I. Kallo, R. Jacob, and G. E. Mann The Isoflavone Equol Mediates Rapid Vascular Relaxation: Ca2+-INDEPENDENT ACTIVATION OF ENDOTHELIAL NITRIC-OXIDE SYNTHASE/Hsp90 INVOLVING ERK1/2 AND Akt PHOSPHORYLATION IN HUMAN ENDOTHELIAL CELL J. Biol. Chem., September 15, 2006; 281(37): 27335 - 27345. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Peluso Flavonoids Attenuate Cardiovascular Disease, Inhibit Phosphodiesterase, and Modulate Lipid Homeostasis in Adipose Tissue and Liver Experimental Biology and Medicine, September 1, 2006; 231(8): 1287 - 1299. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Yang, X.-O. Shu, F. Jin, X. Zhang, H.-L. Li, Q. Li, Y.-T. Gao, and W. Zheng Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1012 - 1017. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kreijkamp-Kaspers, L. Kok, M. L Bots, D. E Grobbee, J. W Lampe, and Y. T van der Schouw Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women Am. J. Clinical Nutrition, January 1, 2005; 81(1): 189 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Atkinson, W. Oosthuizen, S. Scollen, A. Loktionov, N. E. Day, and S. A. Bingham Modest Protective Effects of Isoflavones from a Red Clover-Derived Dietary Supplement on Cardiovascular Disease Risk Factors in Perimenopausal Women, and Evidence of an Interaction with ApoE Genotype in 49-65 Year-Old Women J. Nutr., July 1, 2004; 134(7): 1759 - 1764. [Abstract] [Full Text] |
||||
![]() |
M. Sagara, T. Kanda, M. NJelekera, T. Teramoto, L. Armitage, N. Birt, C. Birt, and Y. Yamori Effects of Dietary Intake of Soy Protein and Isoflavones on Cardiovascular Disease Risk Factors in High Risk, Middle-Aged Men in Scotland J. Am. Coll. Nutr., February 1, 2004; 23(1): 85 - 91. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Jenkins, C. W. Kendall, A. Marchie, A. L Jenkins, L. S. Augustin, D. S Ludwig, N. D Barnard, and J. W Anderson Type 2 diabetes and the vegetarian diet Am. J. Clinical Nutrition, September 1, 2003; 78(3): 610S - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, X. O. Shu, Y.-T. Gao, G. Yang, Q. Li, H. Li, F. Jin, and W. Zheng Soy Food Consumption Is Associated with Lower Risk of Coronary Heart Disease in Chinese Women J. Nutr., September 1, 2003; 133(9): 2874 - 2878. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||